These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 23581650

  • 1. Synthesis, hypoglycaemic, hypolipidemic and PPARγ agonist activities of 5-(2-Alkyl/aryl-6-Arylimidazo[2,1-b][1,3,4]thiadiazol-5-yl)methylene-1,3-thiazolidinediones.
    Khazi MI, Belavagi NS, Kim KR, Gong YD, Khazi IA.
    Chem Biol Drug Des; 2013 Aug; 82(2):147-55. PubMed ID: 23581650
    [Abstract] [Full Text] [Related]

  • 2. Synthesis, hypoglycemic and hypolipidemic activities of novel thiazolidinedione derivatives containing thiazole/triazole/oxadiazole ring.
    Mohammed Iqbal AK, Khan AY, Kalashetti MB, Belavagi NS, Gong YD, Khazi IA.
    Eur J Med Chem; 2012 Jul; 53():308-15. PubMed ID: 22575535
    [Abstract] [Full Text] [Related]

  • 3. Synthesis, characterization and biological evaluation of some novel 2,4-thiazolidinediones as potential cytotoxic, antimicrobial and antihyperglycemic agents.
    Avupati VR, Yejella RP, Akula A, Guntuku GS, Doddi BR, Vutla VR, Anagani SR, Adimulam LS, Vyricharla AK.
    Bioorg Med Chem Lett; 2012 Oct 15; 22(20):6442-50. PubMed ID: 22981328
    [Abstract] [Full Text] [Related]

  • 4. Microwave-assisted synthesis, hypolipidemic and hypoglycemic activity of some novel 2-(4-(2-Amino-6-(4-substituted phenyl)-pyrimidin-4-yl)-phenoxy)-2-methyl propanoic acid derivatives.
    Mokale SN, Elgire RD, Sakle NS, Shinde DB.
    Arch Pharm (Weinheim); 2012 Jan 15; 345(1):22-7. PubMed ID: 22076967
    [Abstract] [Full Text] [Related]

  • 5. Synthesis, biological evaluation and molecular modeling studies of arylidene-thiazolidinediones with potential hypoglycemic and hypolipidemic activities.
    da Costa Leite LF, Veras Mourão RH, de Lima Mdo C, Galdino SL, Hernandes MZ, de Assis Rocha Neves F, Vidal S, Barbe J, da Rocha Pitta I.
    Eur J Med Chem; 2007 Oct 15; 42(10):1263-71. PubMed ID: 17448573
    [Abstract] [Full Text] [Related]

  • 6. Synthesis and biological evaluation of some novel cyclic-imides as hypoglycaemic, anti-hyperlipidemic agents.
    Abdel-Aziz AA, El-Azab AS, Attia SM, Al-Obaid AM, Al-Omar MA, El-Subbagh HI.
    Eur J Med Chem; 2011 Sep 15; 46(9):4324-9. PubMed ID: 21783284
    [Abstract] [Full Text] [Related]

  • 7. Dual PPAR-alpha and -gamma activators derived from novel benzoxazinone containing thiazolidinediones having antidiabetic and hypolipidemic potential.
    Madhavan GR, Chakrabarti R, Reddy KA, Rajesh BM, Balraju V, Rao PB, Rajagopalan R, Iqbal J.
    Bioorg Med Chem; 2006 Jan 15; 14(2):584-91. PubMed ID: 16198573
    [Abstract] [Full Text] [Related]

  • 8. Novel phthalazinone and benzoxazinone containing thiazolidinediones as antidiabetic and hypolipidemic agents.
    Madhavan GR, Chakrabarti R, Kumar SK, Misra P, Mamidi RN, Balraju V, Kasiram K, Babu RK, Suresh J, Lohray BB, Lohrayb VB, Iqbal J, Rajagopalan R.
    Eur J Med Chem; 2001 Jan 15; 36(7-8):627-37. PubMed ID: 11600232
    [Abstract] [Full Text] [Related]

  • 9. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists.
    Darwish KM, Salama I, Mostafa S, Gomaa MS, Helal MA.
    Eur J Med Chem; 2016 Feb 15; 109():157-72. PubMed ID: 26774923
    [Abstract] [Full Text] [Related]

  • 10. Synthesis and antihyperglycemic activity profiles of novel thiazolidinedione derivatives.
    Bhat BA, Ponnala S, Sahu DP, Tiwari P, Tripathi BK, Srivastava AK.
    Bioorg Med Chem; 2004 Nov 15; 12(22):5857-64. PubMed ID: 15498661
    [Abstract] [Full Text] [Related]

  • 11. Synthesis and pharmacological evaluation of substituted 5-[4-[2-(6,7-dimethyl-1,2,3,4-tetrahydro-2-oxo-4-quinoxalinyl)ethoxy]phenyl]methylene]thiazolidine-2,4-dione derivatives as potent euglycemic and hypolipidemic agents.
    Gupta D, Ghosh NN, Chandra R.
    Bioorg Med Chem Lett; 2005 Feb 15; 15(4):1019-22. PubMed ID: 15686904
    [Abstract] [Full Text] [Related]

  • 12. Thiazolidin-4-one and thiazinan-4-one derivatives analogous to rosiglitazone as potential antihyperglycemic and antidyslipidemic agents.
    Raza S, Srivastava SP, Srivastava DS, Srivastava AK, Haq W, Katti SB.
    Eur J Med Chem; 2013 May 15; 63():611-20. PubMed ID: 23567949
    [Abstract] [Full Text] [Related]

  • 13. Design, synthesis, and structure-activity relationship studies of novel 2,4,6-trisubstituted-5-pyrimidinecarboxylic acids as peroxisome proliferator-activated receptor gamma (PPARgamma) partial agonists with comparable antidiabetic efficacy to rosiglitazone.
    Seto S, Okada K, Kiyota K, Isogai S, Iwago M, Shinozaki T, Kitamura Y, Kohno Y, Murakami K.
    J Med Chem; 2010 Jul 08; 53(13):5012-24. PubMed ID: 20527969
    [Abstract] [Full Text] [Related]

  • 14. Synthesis and pharmacological evaluation of novel benzoylazole-based PPAR α/γ activators.
    Ushiroda K, Maruta K, Takazawa T, Nagano T, Taiji M, Kohno T, Sato Y, Horai S, Yanagi K, Nagata R.
    Bioorg Med Chem Lett; 2011 Apr 01; 21(7):1978-82. PubMed ID: 21377875
    [Abstract] [Full Text] [Related]

  • 15. Design and synthesis of a novel class of dual PPARgamma/delta agonists.
    Gonzalez IC, Lamar J, Iradier F, Xu Y, Winneroski LL, York J, Yumibe N, Zink R, Montrose-Rafizadeh C, Etgen GJ, Broderick CL, Oldham BA, Mantlo N.
    Bioorg Med Chem Lett; 2007 Feb 15; 17(4):1052-5. PubMed ID: 17129725
    [Abstract] [Full Text] [Related]

  • 16. Modulation of PPAR subtype selectivity. Part 2: Transforming PPARα/γ dual agonist into α selective PPAR agonist through bioisosteric modification.
    Zaware P, Shah SR, Pingali H, Makadia P, Thube B, Pola S, Patel D, Priyadarshini P, Suthar D, Shah M, Jamili J, Sairam KV, Giri S, Patel L, Patel H, Sudani H, Patel H, Jain M, Patel P, Bahekar R.
    Bioorg Med Chem Lett; 2011 Jan 15; 21(2):628-32. PubMed ID: 21195611
    [Abstract] [Full Text] [Related]

  • 17. Molecular design, synthesis, and hypoglycemic and hypolipidemic activities of novel pyrimidine derivatives having thiazolidinedione.
    Lee HW, Kim BY, Ahn JB, Kang SK, Lee JH, Shin JS, Ahn SK, Lee SJ, Yoon SS.
    Eur J Med Chem; 2005 Sep 15; 40(9):862-74. PubMed ID: 15908051
    [Abstract] [Full Text] [Related]

  • 18. Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.
    Sauerberg P, Pettersson I, Jeppesen L, Bury PS, Mogensen JP, Wassermann K, Brand CL, Sturis J, Wöldike HF, Fleckner J, Andersen AS, Mortensen SB, Svensson LA, Rasmussen HB, Lehmann SV, Polivka Z, Sindelar K, Panajotova V, Ynddal L, Wulff EM.
    J Med Chem; 2002 Feb 14; 45(4):789-804. PubMed ID: 11831892
    [Abstract] [Full Text] [Related]

  • 19. Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.
    Liu W, Lau F, Liu K, Wood HB, Zhou G, Chen Y, Li Y, Akiyama TE, Castriota G, Einstein M, Wang C, McCann ME, Doebber TW, Wu M, Chang CH, McNamara L, McKeever B, Mosley RT, Berger JP, Meinke PT.
    J Med Chem; 2011 Dec 22; 54(24):8541-54. PubMed ID: 22070604
    [Abstract] [Full Text] [Related]

  • 20. Antidiabetic and hypolipidemic potential of DRF 2519--a dual activator of PPAR-alpha and PPAR-gamma.
    Chakrabarti R, Misra P, Vikramadithyan RK, Premkumar M, Hiriyan J, Datla SR, Damarla RK, Suresh J, Rajagopalan R.
    Eur J Pharmacol; 2004 May 03; 491(2-3):195-206. PubMed ID: 15140637
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.